Programmed cell death protein 1 (PD-1) inhibitors have shown disappointing results in relapsed/refractory DLBCL with an ORR of 3–10% with nivolumab monotherapy [67]. This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.